J Biol Chem, Vol. 274, Issue 35, 24799-24807, August 27, 1999
Rapid Nucleolytic Degradation of the Small Cytoplasmic Y RNAs
during Apoptosis*
Saskia A.
Rutjes,
Annemarie
van der Heijden,
Paul J.
Utz
§,
Walther J.
van Venrooij, and
Ger J. M.
Pruijn¶
From the Department of Biochemistry, University of Nijmegen,
P. O. Box 9101, NL-6500 HB Nijmegen, The Netherlands and the
Department of Medicine, Division of Rheumatology,
Immunology and Allergy, Brigham & Women's Hospital,
Boston, Massachusetts 02115
 |
ABSTRACT |
We have investigated the fate of the RNA
components of small ribonucleoprotein particles in apoptotic cells. We
show that the cytoplasmic Ro ribonucleoprotein-associated Y RNAs are
specifically and rapidly degraded during apoptosis via a
caspase-dependent mechanism. This is the first study
describing the selective degradation of a specific class of small
structural RNA molecules in apoptotic cells. Cleavage and subsequent
truncation of Y RNAs was observed upon exposure of cells to a variety
of apoptotic stimuli and were found to be inhibited by Bcl-2, zinc, and
several caspase inhibitors. These results indicate that apoptotic
degradation of Y RNAs is dependent on caspase activation, which
suggests that the nucleolytic activity responsible for hY RNA
degradation is activated downstream of the caspase cascade. The Y RNA
degradation products remain bound by the Ro60 protein and in part also
by the La protein, the only two proteins known to be stably associated
with intact Ro ribonucleoprotein particles. The size of the Y RNA
degradation products is consistent with the protection from degradation
of the most highly conserved region of the Y RNAs by the bound Ro60 and
La proteins. Our results indicate that the rapid abrogation of the yet
unknown function of Y RNAs might be an early step in the systemic
deactivation of the dying cell.
 |
INTRODUCTION |
Apoptosis is a form of cell death characterized by distinct
morphological and biochemical alterations. Morphologically, apoptotic cells are characterized by chromatin condensation, cell shrinkage, fragmentation of the nucleus, and partition of cytoplasm and nucleus into membrane bound-vesicles (apoptotic bodies) (1). During the
last 5 years, many of the molecules that participate in the biochemical
pathway mediating apoptosis have been identified. A major role in this
pathway is played by caspases, cysteine proteases with aspartic acid
substrate specificity (2). Proteins cleaved by caspases appear to be
structural proteins essential for maintaining nuclear and cytoplasmic
architecture and enzymes essential for repair of damaged cell
components (reviewed in Ref. 3). A prominent nuclear event during
apoptosis is internucleosomal cleavage of DNA, recognized as a "DNA
ladder" on conventional agarose gel electrophoresis (4). The
endonuclease activity responsible for apoptotic degradation of
chromosomal DNA has recently been identified (5). The activity depends
on two interacting proteins, one of which contains the endonuclease
activity (caspase-activated deoxyribonuclease
(CAD)1), which is retained in
the cytoplasm in an inactive form due to its association with the
second protein (inhibitor of CAD). Caspase activation in apoptotic
cells leads to cleavage of the inhibitor of CAD, thereby releasing
active CAD resulting in DNA fragmentation in the nuclei (5, 6).
Much less is known about cleavage and degradation of RNA in apoptotic
cells. An increased rate of mRNA turnover has been suggested (7, 8)
as well as mitochondrial 16 S ribosomal RNA degradation (9), but no
nuclease associated with specific RNA cleavage has been described.
Although an increasing number of protein components of
ribonucleoprotein particles (RNPs) have been reported to be modified
during apoptosis, such as the U1-70K protein, which is a component of
the U1 snRNP (10), the 72-kDa component of the signal recognition
particle (11), and the La protein, which is associated with several
RNPs including the Ro RNPs,2
no data have been published on the fate of the RNA components of these
particles during apoptosis. Therefore, we decided to examine the
effects of apoptosis on the cytoplasmic Y RNAs and 7SL RNA, the RNA
components of the Ro RNPs and the signal recognition particle, respectively.
Ro RNPs are a class of small cytoplasmic RNA-protein complexes of
unknown function, which are present in cells of all species studied to
date (reviewed in Ref. 12). In human cells, Ro RNPs consist of one of
four small RNA molecules, termed hY1, hY3, hY4, and hY5 (13). All four
human Y RNAs have been sequenced (14-16) and found to consist of 112, 101, 93, and 84 nucleotides, respectively, although some heterogeneity
at their 3'-ends has been observed. The Y RNAs, which are transcribed
by RNA polymerase III (13), are characterized by a conserved stem
structure formed by extensive base pairing between the evolutionarily
conserved 5'- and 3'-ends. In addition to Y RNAs, Ro RNPs contain at
least two different proteins: the La protein and the 60-kDa Ro protein
(Ro60), whereas the association of a third protein, the 52-kDa Ro
protein (Ro52), is still a matter of debate (17-20). The La protein
binds to the oligouridylate stretch at the 3'-end of the Y RNAs,
whereas Ro60 interacts with the most highly conserved part of the stem
structure (21, 22).
In this study, we observed an extensive, rapid, and selective
nucleolytic degradation of small cytoplasmic RNAs, the Y RNAs, during
apoptosis. This phenomenon was observed upon exposure of the cells to
multiple apoptotic stimuli, and yRNA degradation appeared to be
inhibited by the apoptosis inhibitors Bcl-2 and zinc, as well as by the
caspase inhibitors Ac-YVAD-CMK, Z-DEVD-FMK, and Z-IETD-FMK. The results
of co-immunoprecipitation experiments and size determination of the
apoptotic Y RNA degradation products suggest that the most divergent
regions of the Y RNAs are degraded and that the association of Ro60
with the conserved regions is not disrupted, whereas the association
with La is partially lost.
 |
EXPERIMENTAL PROCEDURES |
Cell Culture--
Jurkat cells, with Bcl-2 (Jurkat/Bcl-2) or
without Bcl-2 (Jurkat/Neo) overexpression, kindly provided by Dr. J. Reed (the Burnham Institute, La Jolla, CA) (23), were grown in RPMI
(Life Technologies, Inc.) medium supplemented with 10%
heat-inactivated fetal calf serum, 200 µg/ml G418 (Life Technologies,
Inc.), 1 µM
-mercaptoethanol, 1 mM sodium
pyruvate, and penicillin and streptomycin. Mouse WR19L cells expressing
human Fas (24) were grown in RPMI (Life Technologies, Inc.) medium
supplemented with 10% heat-inactivated fetal calf serum, 200 µg/ml
G418 (Life Technologies, Inc.), 1 µM
-mercaptoethanol,
1 mM sodium pyruvate, and penicillin and streptomycin. HeLa
cells and HEp-2 cells were grown in Dulbecco's modified Eagle's
medium supplemented with 10% heat-inactivated fetal calf serum and
penicillin and streptomycin. Cells were cultured in 5% CO2
at 37 °C.
Apoptotic RNA Isolation and Preparation of Apoptotic Cell
Extracts--
Jurkat/Bcl-2 and Jurkat/Neo cells and WR19L cells
expressing human Fas (24) were treated with an anti-Fas monoclonal
antibody 7C11, a kind gift of Dr. M. Robertson (Indiana University,
Bloomington, IN), and cells were incubated at 37 °C for the
indicated time periods prior to harvesting. HeLa cells were treated
with 10 µM actinomycin D and HEp-2 cells with 10 µg/ml
anisomycin. Total RNA was isolated by Trizol RNA reagent (Life
Technologies, Inc.), according to the instructions of the manufacturer.
In parallel, cell extracts were prepared by lysis in Nonidet P-40 lysis
buffer (25 mM Tris, pH 7.5, 100 mM KCl, 0.25 mM dithioerythritol, 10 mM MgCl2,
1% Nonidet P-40, protease inhibitor mixture from Roche Molecular
Biochemicals) for 30 min on ice. After centrifugation for 15 min at
12,000 × g, supernatants were analyzed by Western blotting. Monolayer cells were trypsinized, washed with
phosphate-buffered saline, and treated as above. For experiments
utilizing caspase inhibitors, Jurkat cells were cultured in the
presence of either 2% Me2SO, 2 mM
ZnSO4, 2 or 20 µM Ac-YVAD-CMK (caspase-1
inhibitor 2, Calbiochem), 2 or 20 µM Z-DEVD-FMK
(caspase-3 inhibitor 2, Calbiochem), 2 or 20 µM
Z-IETD-FMK (caspase-8 inhibitor 2, Calbiochem) and 2 or 20 µM Z-LEHD-FMK (caspase-9 inhibitor 1, Calbiochem). Subsequently, apoptosis was induced by the addition of anti-Fas monoclonal antibody followed by harvesting after incubations as indicated and lysis as described above.
Northern Blot Analysis--
RNA was size-fractionated on 10%
denaturing polyacrylamide gels and transferred to Hybond N+
filters by electroblotting at 3 V/cm in 0.025 M phosphate,
pH 6.5, for 2 h. Hybridizations were performed overnight at
65 °C in 6× SSC, 5× Denhardt's solution, and 100 µg/ml sheared,
denatured herring sperm DNA with a mixture of 32P-labeled
antisense RNA transcripts of the four hY RNAs, antisense 7SL RNA (25),
kindly provided by Dr. K. Strub (University of Geneva, Switzerland), or
antisense U1 snRNA. Following hybridization, filters were washed twice
at 65 °C in 0.2× SSC, 0.1% SDS and were subjected to autoradiography.
In Vitro Transcription--
Transcription of antisense hY1, hY3,
hY4, hY5, 7SL, and U1 RNA was mainly performed as described (26). To
obtain antisense RNAs, pTZ19-hY1, hY3, hY4, hY5, SP64-7SL, and pGEM-U1
RNA were linearized with EcoRI. In vitro
transcription was performed with T7 RNA polymerase (antisense hY1, hY3,
hY4, and hY5 RNA) or SP6 RNA polymerase (antisense U1 and 7SL RNA).
Transcription and 3'-end labeling of tRNAHis was
performed as described previously (27).
Western Blot Analysis--
Cell extracts were fractionated by
SDS-polyacrylamide gel electrophoresis (10%) and blotted onto
nitrocellulose filter. After blocking the filters in wash buffer (5%
skim milk, phosphate-buffered saline, 0.1% Nonidet P-40) for 1 h
at room temperature, filters were incubated with patient serum H42
(anti-U1-70K) at a dilution of 1:5000 in wash buffer for 1 h at
room temperature. After washing three times for 15 min, binding of
antibodies was visualized by incubation with peroxidase-conjugated
rabbit anti-human antibodies (Dako) followed by chemiluminescence detection.
Metabolic Labeling--
Jurkat/Bcl-2 and Jurkat/Neo cells were
incubated at a density of 2 × 106 cells/ml in
labeling medium (RPMI without phosphate (ICN), 2 mM
GlutaMAX (Life Technologies, Inc.), 5% dialyzed fetal calf serum 1 mM sodium pyruvate, 10 mM Hepes (pH 7.4), and
penicillin and streptomycin). 32P-labeled orthophosphate
was added at a concentration of 33 µCi/ml. After incubating the cells
at 37 °C for 18 h, an equal volume of RPMI (Life Technologies,
Inc.) medium supplemented with 10% heat-inactivated fetal calf serum,
200 µg/ml G418 (Life Technologies, Inc.), 1 µM
-mercaptoethanol, 1 mM sodium pyruvate, 10 mM Hepes (pH 7.4), and penicillin and streptomycin was
added. Cells were treated with an anti-Fas monoclonal antibody 7C11 and
incubated at 37 °C. RNA was isolated either immediately or after
incubation for 1, 2, 3, 4, 6, or 8 h. For protein analysis,
radiolabeled cells were solubilized in Nonidet P-40 lysis buffer at the
indicated time points. Cell lysates were incubated on ice for 30 min,
followed by centrifugation for 15 min at 4 °C at 12,000 × g.
Immunoprecipitation--
To immunoprecipitate either unlabeled
or radiolabeled RNA, protein A-agarose beads were incubated with rabbit
anti-mouse antibodies (Dako) for at least 1 h in
IPP500 (10 mM Tris-HCl (pH 7.5), 500 mM NaCl, 0.05% Nonidet P-40). After washing three times
with IPP500, the beads were incubated with an anti-Ro60
monoclonal antibody (2G10), an anti-La monoclonal antibody (SW5), or an
anti-U1-A monoclonal antibody (9A9) by rotation for at least 1 h
in IPP500. Incubation was followed by washing twice with
IPP500 and twice with TKED (10 mM Tris-HCl (pH
8.0), 100 mM KCl, 1 mM dithioerythritol, 1 mM EDTA, 0.05% Nonidet P-40). After rotating the coated
beads with the extracts in TKED for 2 h at 4 °C, the beads were
washed three times with TKED. RNA was isolated by phenol/chloroform
(1:1) extraction and was precipitated by adding 4 volumes of ethanol and analyzed by 10% denaturing polyacrylamide gel electrophoresis. Radiolabeled RNA was subjected to autoradiography, whereas unlabeled RNA was analyzed by Northern blot hybridization.
 |
RESULTS |
hY RNAs Are Specifically Cleaved Early during Apoptosis--
To
study the effects of apoptosis on the hY RNAs and 7SL RNA, we used two
stably transfected Jurkat cell lines, one overexpressing the apoptosis
inhibitor Bcl-2 (Jurkat/Bcl-2) and the second a transfection vector
control line (Jurkat/Neo). To induce apoptosis, the cells were treated
with a monoclonal antibody reactive with Fas (7C11). Previous studies
have demonstrated that these antibodies very effectively induce
apoptosis in Jurkat cells (11, 28).2 Cells were harvested
either immediately or at the indicated time points after anti-Fas
addition. Total RNA was isolated from cell extracts and analyzed by
Northern blot hybridization using 32P-labeled antisense
hY1, hY3, hY4, hY5, and 7SL RNA probes. The induction of apoptosis was
monitored by the analysis of U1-70K protein cleavage, which leads to
the appearance of a characteristic 40-kDa product. Cleavage of U1-70K,
which is one of the prototypical proteins known to be cleaved during
apoptosis (10), was visualized by immunoblotting of cell extracts using
a patient serum reactive with the U1-70K protein. Analysis of the hY
RNAs revealed that during early stages of apoptosis, these RNAs were
efficiently degraded in anti-Fas-treated Jurkat/Neo cells (Fig.
1A). Degradation products were
already detectable 1.5 h after anti-Fas addition (lane
13), whereas a gradual decrease in the amount of intact hY RNAs
was evident, with the majority of the hY RNAs being degraded within
4 h after anti-Fas addition (compare lane 18 with
lane 11). Although all four hY RNAs were degraded upon
induction of apoptosis, slight differences were observed in the rate of
degradation. The rate of degradation appeared to be related to the size
of the hY RNA; hY1 was degraded most quickly. In contrast, no
degradation of 7SL RNA was observed in these cells (Fig.
1A). The selectivity of degradation of hY RNAs in apoptotic
cells was further substantiated by the lack of detectable degradation
of several other small RNAs, including U snRNAs, tRNAs, and 5 S rRNA
(data not shown).

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 1.
Degradation of hY RNAs during apoptosis.
Jurkat/Bcl-2 (Bcl-2) and Jurkat/Neo (Neo) cells
were treated with the anti-Fas monoclonal antibody 7C11 for various
time periods (indicated above the lanes in hours). A, total
RNA isolated from Jurkat/Bcl-2 (lanes 1-10) and Jurkat/Neo
cells (lanes 11-20) was analyzed by Northern blot
hybridization using a mixture of hY RNA probes (upper panel)
and a 7SL RNA probe (lower panel). The positions of the hY
RNAs, their degradation products, and 7SL RNA are indicated.
B, control for the induction of apoptosis monitored by
U1-70K cleavage, which is visualized by Western blot analysis using a
polyclonal anti-U1-70K serum. The positions of the U1-70K protein and
its apoptotic cleavage product (U1-40K) are indicated. C,
degradation of Y RNAs occurs in cells triggered by the apoptotic
stimuli and in cells derived from other species. Human HeLa cells
treated with actinomycin D (10 µM) (lanes 1 and 2), HEp-2 cells treated with anisomycin (10 µg/ml)
(lanes 3 and 4), and mouse WR19L cells expressing
human Fas (13) treated with anti-Fas monoclonal antibody (lanes
5 and 6) were harvested after incubation for various
time periods (indicated above the lanes). Total RNA was isolated and
analyzed by Northern blot hybridization using a mixture of hY RNA
probes. The positions of the hY RNAs are indicated. Note that in mouse
cells, only mY1 and mY3 are present.
|
|
Degradation of hY RNAs was inhibited in Jurkat cells overexpressing
Bcl-2, because a slight decrease of the amount of hY RNAs was only
detectable 6 h after anti-Fas addition, whereas degradation products did not appear during the first 3 h (lanes
1-10). The delayed degradation of hY RNAs in Jurkat/Bcl-2 cells
in comparison with the Jurkat/Neo cells reflected the different
efficiencies of apoptosis induction in these cells, which was monitored
by cleavage of the U1-70K protein (Fig. 1B) and by flow
cytometry of annexin-V stained cells (results not shown).2
The kinetics of hY RNA degradation appeared to be very similar to that
of U1-70K cleavage, which is known to be mediated by caspase-3, suggesting that hY RNA degradation might also be dependent on caspase activation.
To determine whether degradation of hY RNAs also occurs when apoptosis
is triggered by other stimuli, and in cells derived from other species,
we analyzed apoptotic cell extracts derived from human HeLa cells
treated with actinomycin D (10 µM) (data not shown) or
HEp-2 cells treated with anisomycin (10 µg/ml). Also, apoptotic cell
extracts, derived from mouse WR19L cells expressing human Fas (24) and
treated with anti-Fas monoclonal antibody, were analyzed. Total RNA was
isolated and analysis of Y RNAs by Northern blot hybridization revealed
that Y RNA degradation was observed in all cells tested (Fig.
1C). Induction of apoptosis in all cells was confirmed by
cleavage of the U1-70K protein.
Although the normal turnover rate of hY RNAs is known to be relatively
low, a reduction of the hY RNA levels in apoptotic cells might in
principle be due to either inhibition of RNA polymerase III
transcription or to an increased rate of hY RNA degradation. To exclude
the possibility that the reduction in hY RNA levels was caused by
abrogation of their synthesis and to investigate the association of the
Ro RNP with hY RNAs in apoptotic cells, RNA in Jurkat/Bcl-2 and
Jurkat/Neo cells was radiolabeled by culturing the cells in the
presence of 32P-orthophosphate for 18 h. After
labeling, apoptosis was induced by anti-Fas addition in complete
medium, i.e. in the presence of an excess of unlabeled
phosphate. Cells were lysed either immediately or after incubation for
the indicated time periods, and induction of apoptosis was monitored by
cleavage of the U1-70K protein (data not shown). The results for the
Jurkat/Bcl-2 cells illustrate the low turnover rate of hY RNAs (Fig.
2, lanes 5-11). Even at 8 h after replacement of radiolabeled phosphate with unlabeled phosphate, little or no decrease of radiolabeled hY RNAs was observed, which is indicative of the relatively long half-life of these molecules. This result confirms that the observed decrease in hY RNAs
levels during apoptosis is due to a strongly increased degradation rate
rather than the abrogation of hY RNA synthesis.

View larger version (69K):
[in this window]
[in a new window]
|
Fig. 2.
Stability of hY RNAs in Jurkat cells and Ro
RNP association of hY RNAs during apoptosis. Jurkat/Bcl-2
(Bcl-2) and Jurkat/Neo (Neo) cells were cultured
in the presence of 32P-labeled orthophosphate (in
phosphate-free medium) for 18 h at 37 °C. After replacing the
labeling medium with complete medium, apoptosis was induced by anti-Fas
addition, and cell extracts were prepared either immediately or after
incubations for the indicated time periods (above the lanes). Total RNA
isolated from the 0 and 8 h extracts (lanes 1-4) and
hY RNAs isolated from Jurkat/Bcl-2 extracts (lanes 5-9) and
Jurkat/Neo extracts (lanes 10-14) by immunoprecipitation
with an anti-Ro60 monoclonal antibody (2G10) were analyzed by
denaturing polyacrylamide gel electrophoresis and autoradiography. The
positions of pre-tRNA, tRNA, 5 S rRNA, 5.8 S rRNA, and the hY RNAs are
indicated. The amount of RNA electrophoresed in lanes 1-4
corresponds to 1% of the amount of cell extracts used for hY RNA
isolation.
|
|
Because an immunoprecipitation step was required to isolate the low
abundance hY RNAs from the total pool of radiolabeled RNAs, this
experiment also provided information on the Ro RNP association of
radiolabeled hY RNAs. Immunoprecipitation was performed with an
anti-Ro60 monoclonal antibody (2G10), and co-precipitated RNAs were
analyzed by denaturing polyacrylamide gel electrophoresis and
autoradiography. The results in Fig. 2 show that co-immunoprecipitation of hY RNAs from apoptotic Jurkat/Neo cell extracts decreased during the
first hours after anti-Fas addition and was hardly detectable at the
4 h time point (lanes 10-14). The decrease in hY RNA
precipitation by anti-Ro60 antibodies is likely to be indeed caused by
hY RNA degradation rather than by disruption of the interaction between hY RNAs and Ro60, because the analysis of Ro60 from apoptotic cells by
Western blotting did not reveal detectable changes, such as proteolytic
cleavage (Ref. 28 and data not shown). Moreover, the RNA binding
capacity of Ro60 was not abolished in apoptotic Jurkat cells, as
demonstrated by the co-precipitation of hY RNA degradation products
(see below). It should also be noted that the disappearance of
full-length hY RNAs isolated by immunoprecipitation from radiolabeled
cell extracts resembles the decrease of hY RNA signals obtained by
Northern blot analysis of total RNA (Fig. 1). Taken together, these
results demonstrate that the disappearance of hY RNAs during apoptosis
is indeed due to degradation and that hY RNAs remain in association
with the Ro RNP in apoptotic cells until or even after the
degradation process has been initiated.
The differences in RNA ranging in size approximately from 5 to 5.8 S
rRNA between total radiolabeled RNA isolated either immediately after
anti-Fas addition (Fig. 2, lanes 1 and 3) or
following 8 h of incubation (lanes 2 and 4)
might be due to apoptotic degradation of ribosomal RNA and/or mRNA
(7-9), resulting in higher background signals. Note that due to the
low abundance of radiolabeled hY RNAs, relatively high background
signals of much more abundant RNAs, such as 5 and 5.8 S rRNA (Fig. 2,
lanes 1 and 3), were observed among the
immunoprecipitated RNAs (lanes 5-14).
Effect of Caspase Inhibitors on Degradation of hY
RNAs--
Caspases are not only involved in the activation of
apoptotic proteases; also, caspase-dependent activation of
a deoxyribonuclease has recently been reported (5). To study the role
of caspases in the activation of the nuclease activity responsible for
hY RNA degradation during apoptosis, Jurkat cells were cultured in the
presence of several caspase inhibitors, including zinc sulfate (29),
the caspase-1 inhibitor Ac-YVAD-CMK, the caspase-3 inhibitor Z-DEVD-FMK, the caspase-8 inhibitor Z-IETD-FMK, or the caspase-9 inhibitor Z-LEHD-FMK for 1 h prior to and during anti-Fas
treatment. Cells were harvested either immediately or 4 or 8 h
after anti-Fas addition. Total RNA was isolated and analyzed by
Northern blotting using hY RNA probes and a 7SL RNA probe as a control.
Fig. 3A demonstrates that hY
RNA degradation was completely inhibited in Jurkat cells cultured in
the presence of zinc sulfate (Fig. 3A, lanes 4-6). hY RNA
degradation was also clearly inhibited by the addition of Ac-YVAD-CMK,
Z-DEVD-FMK and Z-IETD-FMK (Fig. 3B, lanes 3-8) in
comparison with the control incubation with 2% Me2SO (Fig.
3B, lane 2). In contrast, the caspase-9 inhibitor Z-LEHD-FMK
only poorly affected hYRNA degradation (Fig. 3B, lanes 9-10). As expected, the addition of these inhibitors had no
effect on 7SL RNA signals (Fig. 3, lower panels). As a
control for the inhibitory activity of the tetrapeptide inhibitors, the
cell extracts were also analyzed for U1-70K cleavage, which is known to
be sensitive to Ac-DEVD-CHO (10, 28, 30). Cleavage of the U1-70K
protein was indeed inhibited by ZnSO4 and the caspase-1,
caspase-3, and caspase-8 inhibitors and to a lesser extent by the
caspase-9 inhibitor (data not shown). These results demonstrate that
the apoptotic degradation of hY RNAs is dependent on caspase
activation.

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 3.
Effect of caspase inhibitors on hY RNA
degradation. A, Jurkat/Neo cells were cultured for
1 h in the absence (lanes 1-3) or presence
(lanes 4-6) of 2 mM ZnSO4.
Subsequently, the cells were incubated with the anti-Fas monoclonal
antibody 7C11 for 0, 4, or 8 h, followed by total RNA isolation
and Northern blot analysis by hybridization with a mixture of hY RNA
probes (upper panels) and with a 7SL probe (lower
panels). The positions of the hY RNAs, their degradation products,
and 7SL RNA are indicated. B, Jurkat/Neo cells were cultured
for 1 h in the presence of 2% Me2SO (lanes
1 and 2), 2 µM (lanes 3, 5, 7, and 9) or 20 µM (lanes 4, 6, 8, and
10) Ac-YVAD-CMK (lanes 3 and 4),
Z-DEVD-FMK (lanes 5 and 6), Z-IETD-FMK
(lanes 7 and 8), or Z-LEHD-FMK (lanes
9 and 10), which were all dissolved in
Me2SO (final concentration in culture, 2%
Me2SO). Subsequently, the anti-Fas monoclonal antibody 7C11
was added, and the cells were incubated for 4 h. The RNA analysis
was performed as described in the legend to Fig. 3A.
Material from nonapoptotic control cells (C) is analyzed in
lane 1, whereas lane 2 contains apoptotic
(A) material (from cells cultured for 4 h in the
presence of anti-Fas antibody). The positions of the hY RNAs, their
degradation products, and 7SL RNA (lower panels) are
indicated.
|
|
The Ro60 and La Proteins Remain Associated with the Apoptotic
Degradation Products of hY RNAs--
The results described above
indicate that hY RNAs remain associated with the Ro60 protein until or
possibly even during the degradation process. Therefore, it was
possible that at least some of the degradation products were still
bound by either the Ro60 or the La protein, the two proteins that are
directly bound to the hY RNAs in Ro RNP complexes. To investigate the
potential interaction of these proteins with the apoptotic degradation
products hY RNAs, immunoprecipitation experiments were performed with
monoclonal anti-Ro60 (2G10) and anti-La (SW5) antibodies. Cell extracts
were prepared at various time points after the addition of anti-Fas antibody and RNA was analyzed by Northern blot hybridization either directly isolated from cell extracts or following immunoprecipitation. Fig. 4A shows RNA isolated
from cell extracts, corresponding with 10% of the cell extracts used
for immunoprecipitation. As is shown in Fig. 4, B and
C, both the full-length hY RNAs and at least part of the
degradation products were co-immunoprecipitated with anti-Ro60 (Fig.
4B) and anti-La (Fig. 4C) antibodies. This
strongly suggests that both proteins remain associated with the hY RNAs during the nucleolytic process and thus with the respective binding site containing degradation products of the hY RNAs. The anti-Ro60 antibody co-precipitated the degradation products much more efficiently than the anti-La antibody, which might indicate that although both
antibodies seem to co-precipitate the same set of degradation products,
the La binding site might be partially lost. A control immunoprecipitation was performed with a monoclonal antibody (9A9) to
the U1A protein, a protein specifically associated with the U1 snRNP.
As expected, U1 snRNA was not co-precipitated with anti-Ro60 and
anti-La antibodies, and no hY RNAs were co-precipitated with the
anti-U1A antibodies (Fig. 4D). In contrast, U1 snRNA was
efficiently precipitated by the anti-U1A antibodies, substantiating the
specificity of the immunoprecipitations.

View larger version (43K):
[in this window]
[in a new window]
|
Fig. 4.
The Ro60 and La proteins are associated with
the apoptotic hY RNA degradation products. Jurkat/Neo cells were
treated with anti-Fas antibody, and cell extracts were prepared at the
indicated time points. RNPs were isolated by immunoprecipitation with
anti-Ro60 (2G10), anti-La (SW5), or anti-U1A (9A9) monoclonal
antibodies. RNAs isolated from the immunoprecipitates were analyzed by
Northern blot hybridization using a mixture of hY RNA probes
(upper panels) or a U1 snRNA probe (lower
panels). A, total RNA isolated from cell extracts,
corresponding to 10% of extracts used for immunoprecipitations (note
that due to an electrophoresis artifact the amount of total RNA in
lane 1 is less than 10% of input material); RNA
co-immunoprecipitated by anti-Ro60 (2G10) (B), anti-La (SW5)
(C), and anti-U1A (9A9) (D). The positions of the
hY RNAs, their degradation products, and U1 RNA are indicated.
|
|
Determination of the Length of the Apoptotic Degradation Products
of hY RNAs--
To determine the length of the apoptotic degradation
products of the hY RNAs, 32P-labeled Jurkat/Neo cell
extracts were used to isolate hY RNA degradation products by
immunoprecipitation with anti-Ro60 monoclonal antibody 2G10. An
anti-Ro60 antibody was used because the degradation products were
efficiently co-precipitated by this antibody and because the pattern of
degradation products precipitated by this antibody was
indistinguishable from the pattern observed in total RNA (which was
more evident when a longer exposure of Fig. 4A was compared
with Fig. 4B; data not shown). Precipitated RNAs were
analyzed by denaturing polyacrylamide gel electrophoresis and
autoradiography (Fig. 5A). As
RNA size marker 3'-end-labeled tRNAHis (27), either
partially digested under denaturing conditions by RNase T1 (lane
1) or denatured at 94 °C in the presence of 10 mM
MgCl2 (lane 2), was used. Consistent with the
results shown in Figs. 1-4, 2 h after anti-Fas addition, a
decrease in the amount of full-length hY RNAs was observed, with the
simultaneous appearance of the degradation products (lane
5). The result showed that the apoptotic hY RNA degradation
products range in size from 22 to 36 nucleotides. The heterogeneity in
size of these fragments is at least in part due to (i) the fact that
the fragments are derived from four distinct RNAs (hY1, hY3, hY4, and
hY5), (ii) the known 3'-end heterogeneity of native hY RNAs, and (iii)
the fact that both 5'-end and 3'-end fragments of these RNAs will be
present in the immunoprecipitate, taking into account that the Ro60
binding site is composed of a hybrid of these fragments.

View larger version (51K):
[in this window]
[in a new window]
|
Fig. 5.
Determination of the length of the hY RNA
degradation products. Jurkat/Neo cells were labeled by culturing
in the presence of 32P-orthophosphate in phosphate-free
medium for 18 h at 37 °C. After the addition of an equal volume
of phosphate-containing medium, apoptosis was induced by anti-Fas
addition. A, hY RNAs were isolated from cell extracts
prepared at the time points indicated above the lanes by
immunoprecipitation with an anti-Ro60 monoclonal antibody (2G10). RNA
was isolated from the immunoprecipitates and analyzed by denaturing
polyacrylamide gel electrophoresis and autoradiography. As the RNA size
marker, 3'-end-labeled tRNAHis (4), either partially
digested under denaturing conditions by RNase T1 (M, lane 1)
or partially hydrolyzed at 94 °C in the presence of 10 mM MgCl2 (L, lane 2), was
electrophoresed in parallel. RNA marker lengths are indicated on the
left, and the positions of the hY RNAs and their degradation
products are indicated on the right. B, hY RNA
degradation products were isolated from cell extracts prepared at the
time points indicated above the lanes by immunoprecipitation with an
anti-Ro60 monoclonal antibody (2G10) (lanes 1-3) or with an
anti-La monoclonal antibody (SW5) (lanes 4-6). RNA was
isolated from the immunoprecipitates and analyzed by denaturing
polyacrylamide gel electrophoresis and autoradiography. The length of
the hY RNA degradation products (see A) is indicated on the
right.
|
|
The apoptotic degradation products of hY RNAs were more efficiently
precipitated by anti-Ro60 antibodies than by anti-La antibodies (Fig.
4, B and C), indicating that the La association
and/or the La binding site might be partially lost. To study this in
more detail, we also isolated hY RNA degradation products by
immunoprecipitation with anti-La monoclonal antibody SW5 and compared
these products with the degradation products immunoprecipitated with
anti-Ro60 antibodies by denaturing gel electrophoresis (Fig.
5B). The results showed that in addition to the differences
in efficiency of precipitation, the patterns of co-precipitated
molecules were different. Most notably, the smallest apoptotic hY RNA
degradation products immunoprecipitated with anti-Ro60 antibodies,
ranging in size from 22 to 25 nucleotides, were not immunoprecipitated
by anti-La antibodies (Fig. 5B), which strongly suggests
that these degradation products have lost the 3' oligouridine stretch.
Although all the other bands (27-36 nucleotides), with the exception
of the 31-nucleotide-long molecule(s), were detectable in the anti-La
selected material, their relative intensities showed some variation,
which is of course not surprising if we take into account that these
bands also contain molecules corresponding to the 5'-end of the hY
RNAs, which are not present in the anti-La precipitate when they are
annealed with 3'-fragments from which the La binding site has been removed.
 |
DISCUSSION |
Previous studies have demonstrated that the Ro RNP-associated Ro
proteins and La are clustered in two distinct populations of blebs at
the surface of apoptotic cells (31). The Ro52 protein is present in
small apoptotic blebs together with fragmented endoplasmic reticulum
and ribosomes. The larger blebs, called apoptotic bodies, contain the
La protein, the Ro60 protein, small nuclear ribonucleoproteins, and
nucleosomal DNA (31, 32). A more detailed analysis of both Ro proteins
as present in apoptotic cells by Western blotting did not show obvious
changes, such as a proteolytic cleavage (33). However, we observed
recently that the La protein is rapidly dephosphorylated during
apoptosis, and in addition, a subset of the La molecules is
cleaved.2 In this study, we have demonstrated that the RNA
components of Ro RNPs, the Y RNAs, are efficiently degraded early
during apoptosis, whereas several other small RNAs, including 7SL RNA,
U snRNAs, tRNAs, and 5 S rRNA, are not detectably affected. Degradation of Y RNAs was observed in a variety of cell types and after induction of apoptosis by a variety of stimuli. Apoptotic Y RNA degradation was
inhibited by the caspase-1 inhibitor Ac-YVAD-CMK, the caspase-3 inhibitor Z-DEVD-FMK, and the caspase-8 inhibitor Z-IETD-FMK after anti-Fas induced apoptosis, strongly suggesting that this process is
dependent on caspase activation. Activation of effector caspases, such
as caspase-3 and related proteases, can be mediated by the activation
of initiator caspases, such as caspase-8 and -9. Caspase-8 is activated
by signals from death receptors at the cell surface (e.g.
the Fas receptor) (34), whereas caspase-9 is activated by Apaf1 in
cells undergoing drug-induced apoptosis (34, 35). Y RNA degradation is
observed in anti-Fas-treated cells as well as in cells treated with
actinomycin D and anisomycin, indicating that activation of the
nuclease involved can be induced by both pathways, consistent with the
activation of the nucleolytic activity by a general effector caspase.
Such a mechanism is supported by the inhibitory effect on hY RNA
degradation of the caspase-1, -3, and -8 inhibitors in anti-Fas-treated
cells. These results demonstrate that Fas-induced hY RNA degradation is
dependent on caspase-8 activation and suggest that a subsequently
activated effector caspase, such as, e.g. caspase-1 or
caspase-3, is involved in activation of the nucleolytic activity. As
expected, hardly any inhibition of hY RNA degradation was observed by
the caspase-9 inhibitor in anti-Fas induced apoptotic cells, in
agreement with the fact that caspase-9 does not play a major role in
this pathway (34). It should be stressed that the data obtained with
the tetrapeptide caspase inhibitors should be interpreted with care, because the specificity of the inhibitors is not absolute (36, 37). For
instance, the slight inhibition observed with the caspase-9 inhibitor
might be due to cross-inhibition of another caspase. We conclude that
apoptotic hY RNA degradation is caspase-dependent and
that the ribonuclease(s) involved is most likely activated by the
action of one or more effector caspases. The size and protein binding
characteristics of the most stable apoptotic degradation products
suggest that the central parts of the Y RNAs are cleaved by an
endonuclease activity and that these regions are further degraded up to
the region that is protected by the stably bound Ro60 and La proteins.
At present, little is known about degradation or cleavage of RNA in
apoptotic cells. An increased rate of mRNA turnover has been
reported (7, 8) as well as mitochondrial ribosomal RNA degradation (9),
but so far, no nuclease activity associated with specific RNA
degradation has been described. The best characterized nuclease that is
specifically activated in apoptotic cells is the DNase involved in
internucleosomal cleavage of chromatin, resulting in the typical DNA
ladder. In nonapoptotic cells, this CAD is located in the
cytoplasm in a complex with the inhibitor of CAD. Upon induction of
apoptosis, the inhibitor is cleaved by caspase-3, thereby releasing
active CAD, which then is able to enter the nucleus (5). Human
homologues for CAD and the inhibitor of CAD, which were initially
characterized after purification from mouse cells, have been described
recently and were designated CPAN and DFF45, respectively (38, 39). CAD
and CPAN have no significant homology to known nuclease protein
families and may, therefore, represent a new class of endonucleases
(38). Because apoptotic degradation of Y RNAs is also dependent on
caspase activation, it is tempting to speculate that the (endo)nuclease
involved in apoptotic Y RNA degradation might be a member of this new
class of endonucleases.
The secondary structure of Y RNAs is characterized by a pyrimidine-rich
internal loop and a long stem structure formed by extensive base
pairing between the highly conserved 5'- and 3'-ends (Fig.
6). Binding of the Ro60 protein to the Y
RNAs has been extensively studied (21, 22, 40). The central part of the
conserved stem structure, highlighted in Fig. 6 by the boxed
areas, appeares to be essential for binding the Ro60 protein (40).
The binding of the Ro60 protein, possibly in combination with the La
protein, protected the RNA against pancreatic ribonuclease digestion
(22). Because the apoptotic degradation products of the hY RNAs are at
least in part associated with Ro60 and the La protein, which binds to
the oligouridylate stretch at the 3'-end of the RNAs, it is likely that
protection against the RNA degrading activity by these proteins also
occurs in apoptotic cells.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 6.
Secondary structures of the hY RNAs and
possible apoptotic degradation products. The secondary structures
shown are according to Van Gelder et al. (43). The regions
that are involved in Ro60 binding, derived from data published by Green
et al. (40), are boxed. The regions harboring the
potential termini of the smallest (22 nucleotides) and largest (36 nucleotides) degradation products associated with Ro60 are indicated
with arrows. Thin arrows border the regions for
termini of 5'-end fragments, whereas bold arrows border the
regions for termini of 3'-end fragments of the hY RNAs. Note that the
positions of the bold arrows bordering the 22 nucleotides
3'-terminal fragments, which represent fragments that are not
associated with the La protein, are based on the assumption that the
single-stranded nucleotides at the 3'-ends are removed. Dotted
arrows mark terminal fragments of 27 nucleotides, i.e.
the minimal length of the fragments that co-immunoprecipitate with the
anti-La monoclonal antibody.
|
|
The length of the Ro60-associated apoptotic degradation products, as
determined in a denaturing gel system, ranges from approximately 22 to
36 nucleotides (Fig. 5A), whereas the length of the
degradation products that remain associated with the La protein ranges
from 27 to 36 nucleotides. The size heterogeneity is most likely, at least in part, explained by the hY RNA heterogeneity, the 3'-end heterogeneity of individual hY RNAs, and the presence of fragments derived from both the 5'- and 3'-ends of the RNAs. In addition, fragments derived from the 5'-end of the RNAs might still contain a
triphosphate entity at their 5'-end, whereas, also, the phosphorylation state at the termini of the fragments generated during apoptosis is
unknown. The negative charge of terminal phosphates is known to
influence the mobility of relatively small molecules in denaturing polyacrylamide gels. This may explain the "half-nucleotide"
migration shifts of the most prominent hY RNA degradation products with respect to the marker lane (Fig. 5A), and this makes it
impossible to designate the size of the degradation products to
one-nucleotide resolution. Most of the hY RNA degradation products will
be derived from hY5 RNA, because in nonapoptotic cells, this RNA is
most efficiently labeled, consistent with the relative abundance of hY
RNAs in human cells (41). A schematic representation of the hY RNAs and
the regions in which the termini of the degradation products map are
shown in Fig. 6. From these results, we conclude that the degradation
products are not simply the result of a single cleavage event. Most
likely, an initial endonucleolytic cleavage occurs in the central part
of the hY RNAs, possibly in the pyrimidine-rich internal loop,
subsequently followed by either exonuclease digestion starting at the
initial cleavage site or additional endonucleolytic cleavages. The
slight decrease in the sizes of the degradation products observed
between 2 and 6 h after the induction of apoptosis suggests the
involvement of an exonucleolytic activity. The exclusive association of
Ro60 and not La with the group of smaller degradation products (22-25
nucleotides) strongly suggests that also from the 3'-end of the hY
RNAs, nucleotides may be removed in apoptotic cells, resulting in
disruption of the La binding site.
Many caspase substrates are proteins involved in important cellular
processes, such as cell cycle regulation, signaling, DNA repair, cell
homeostasis, and cell survival, suggesting that proteolytic disabling
of certain key proteins directly contributes to the irreversibility of
the apoptotic process. In view of their rapid, specific, and efficient
degradation during apoptosis, this might also be true for Y RNAs.
Unfortunately, the function of Ro RNPs is still unknown, although
recently, a role for Y RNAs in the translational control of ribosomal
protein mRNAs, and possibly other 5'-terminal
oligopyrimidine-containing mRNAs, has been suggested (42). The
possible involvement in the systemic disassembly of the dying cell
might give new clues to elucidate the function of Ro RNPs.
 |
ACKNOWLEDGEMENTS |
We thank Dr. K. Strub (University of Geneva,
Switzerland) for providing the 7SL RNA clone, Dr. M. Robertson (Indiana
University, Bloomington, IN) for providing the anti-Fas monoclonal
antibody 7C11, Dr. J. Reed (Burnham Institute, La Jolla, CA) for the
gift of the transfected Jurkat cells, and Dr. W. J. Hendriks
(University of Nijmegen, The Netherlands) for providing the transfected
WR19L cells.
 |
FOOTNOTES |
*
This work was supported in part by the Netherlands
Foundation for Chemical Research with financial aid from the
Netherlands Organization for Scientific Research.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Supported by the Arthritis Foundation, the Scleroderma Foundation,
Inc., National Institutes of Health Grant K08AI01521, the Arthritis
National Research Foundation, and Harvard Skin Disease Research Center
Grant AR42689.
¶
To whom correspondence should be addressed. Tel.:
31-24-361-6847; Fax: 31-24-354-0525; E-mail:
G.Pruijn@bioch.kun.nl.
2
S. A. Rutjes, P. J. Utz, A. van der
Heijden, C. Broekhuis, W. J. van Venrooij, and G. J. M. Pruijn, submitted for publication.
 |
ABBREVIATIONS |
The abbreviations used are:
CAD, caspase-activated DNase;
RNP, ribonucleoprotein particle;
sn, small
nuclear.
 |
REFERENCES |
| 1.
|
Cohen, J. J.,
Duke, R. C.,
Fadok, V. A.,
and Sellins, K. S.
(1992)
Annu. Rev. Immunol.
10,
267-293[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Alnemri, E. S.,
Livingston, D. J.,
Nicholson, D. W.,
Salvesen, G.,
Thornberry, N. A.,
Wong, W. W.,
and Yuan, J.
(1996)
Cell
87,
171[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Cohen, G. M.
(1997)
Biochem. J.
326,
1-16
|
| 4.
|
Wyllie, A. H.
(1980)
Nature
284,
555-556[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Enari, M.,
Sakahira, H.,
Yokoyama, H.,
Okawa, K.,
Iwamatsu, A.,
and Nagata, S.
(1998)
Nature
391,
43-50[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Sakahira, H.,
Enari, M.,
and Nagata, S.
(1998)
Nature
391,
96-99[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Mondino, A.,
and Jenkins, M. K.
(1995)
J. Biol. Chem.
270,
26593-26601[Abstract/Free Full Text]
|
| 8.
|
Owens, G. P.,
and Cohen, J. J.
(1992)
Cancer Metastasis Rev.
11,
149-156[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Crawford, D. R.,
Lauzon, R. J.,
Wang, Y.,
Mazurkiewicz, J. E.,
Schools, G. P.,
and Davies, K. J.
(1997)
Free Radical Biol. Med.
22,
1295-1300[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Casciola-Rosen, L. A.,
Miller, D. K.,
Anhalt, G. J.,
and Rosen, A.
(1994)
J. Biol. Chem.
269,
30757-30760[Abstract/Free Full Text]
|
| 11.
|
Utz, P. J.,
Hottelet, M.,
Le, T. M.,
Kim, S. J.,
Geiger, M. E.,
Van Venrooij, W. J.,
and Anderson, P.
(1998)
J. Biol. Chem.
273,
35362-35370[Abstract/Free Full Text]
|
| 12.
|
Pruijn, G. J. M.,
Simons, F. H. M.,
and Van Venrooij, W. J.
(1997)
Eur. J. Cell Biol.
74,
123-132[Medline]
[Order article via Infotrieve]
|
| 13.
|
Hendrick, J. P.,
Wolin, S. L.,
Rinke, J.,
Lerner, M. R.,
and Steitz, J. A.
(1981)
Mol. Cell. Biol.
1,
1138-1149[Abstract/Free Full Text]
|
| 14.
|
Kato, N.,
Hoshino, H.,
and Harada, F.
(1982)
Biochem. Biophys. Res. Commun.
108,
363-370[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
O'Brien, C. A.,
and Harley, J. B.
(1990)
EMBO J.
9,
3683-3689[Medline]
[Order article via Infotrieve]
|
| 16.
|
Wolin, S. L.,
and Steitz, J. A.
(1983)
Cell
32,
735-744[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Ben Chetrit, E.,
Chan, E. K.,
Sullivan, K. F.,
and Tan, E. M.
(1988)
J. Exp. Med.
167,
1560-1571[Abstract/Free Full Text]
|
| 18.
|
Boire, G.,
Gendron, M.,
Monast, N.,
Bastin, B.,
and Menard, H. A.
(1995)
Clin. Exp. Immunol.
100,
489-498[Medline]
[Order article via Infotrieve]
|
| 19.
|
Peek, R.,
Pruijn, G. J. M.,
and Van Venrooij, W. J.
(1994)
J. Immunol.
153,
4321-4329[Abstract]
|
| 20.
|
Slobbe, R. L.,
Pluk, W.,
Van Venrooij, W. J.,
and Pruijn, G. J. M.
(1992)
J. Mol. Biol.
227,
361-366[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Pruijn, G. J. M.,
Slobbe, R. L.,
and Van Venrooij, W. J.
(1991)
Nucleic Acids Res.
19,
5173-5180[Abstract/Free Full Text]
|
| 22.
|
Wolin, S. L.,
and Steitz, J. A.
(1984)
Proc. Natl. Acad. Sci. U. S. A.
81,
1996-2000[Abstract/Free Full Text]
|
| 23.
|
Torigoe, T.,
Millan, J. A.,
Takayama, S.,
Taichman, R.,
Miyashita, T.,
and Reed, J. C.
(1994)
Cancer Res.
54,
4851-4854[Abstract/Free Full Text]
|
| 24.
|
Cuppen, E.,
Nagata, S.,
Wieringa, B.,
and Hendriks, W.
(1997)
J. Biol. Chem.
272,
30215-30220[Abstract/Free Full Text]
|
| 25.
|
Strub, K.,
Moss, J.,
and Walter, P.
(1991)
Mol. Cell. Biol.
11,
3949-3959[Abstract/Free Full Text]
|
| 26.
|
Scherly, D.,
Boelens, W.,
Van Venrooij, W. J.,
Dathan, N. A.,
Hamm, J.,
and Mattaj, I. W.
(1989)
EMBO J.
8,
4163-4170[Medline]
[Order article via Infotrieve]
|
| 27.
|
Brouwer, R.,
Vree Egberts, W.,
Jongen, P. H.,
Van Engelen, B. G. M.,
and Van Venrooij, W. J.
(1998)
Arthritis Rheum.
41,
1428-1437[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Casiano, C. A.,
Martin, S. J.,
Green, D. R.,
and Tan, E. M.
(1996)
J. Exp. Med.
184,
765-770[Abstract/Free Full Text]
|
| 29.
|
Takahashi, A.,
Alnemri, E. S.,
Lazebnik, Y. A.,
Fernandes-Alnemri, T.,
Litwack, G.,
Moir, R. D.,
Goldman, R. D.,
Poirier, G. G.,
Kaufmann, S. H.,
and Earnshaw, W. C.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
8395-8400[Abstract/Free Full Text]
|
| 30.
|
Casciola Rosen, L.,
Nicholson, D. W.,
Chong, T.,
Rowan, K. R.,
Thornberry, N. A.,
Miller, D. K.,
and Rosen, A.
(1996)
J. Exp. Med.
183,
1957-1964[Abstract/Free Full Text]
|
| 31.
|
Casciola Rosen, L. A.,
Anhalt, G.,
and Rosen, A.
(1994)
J. Exp. Med.
179,
1317-1330[Abstract/Free Full Text]
|
| 32.
|
Rosen, A.,
and Casciola Rosen, L.
(1999)
Cell Death Differ.
6,
6-12
[CrossRef][Medline]
[Order article via Infotrieve] |
| 33.
|
Porter, A. G.,
Ng, P.,
and Janicke, R. U.
(1997)
BioEssays
19,
501-507[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Thornberry, N. A.,
and Lazebnik, Y.
(1998)
Science
281,
1312-1316[Abstract/Free Full Text]
|
| 35.
|
Cecconi, F.,
Alvarez Bolado, G.,
Meyer, B. I.,
Roth, K. A.,
and Gruss, P.
(1998)
Cell
94,
727-737[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Garcia-Calvo, M.,
Peterson, E. P.,
Leiting, B.,
Ruel, R.,
Nicholson, D. W.,
and Thornberry, N. A.
(1998)
J. Biol. Chem.
273,
32608-32613[Abstract/Free Full Text]
|
| 37.
|
Thornberry, N. A.,
Rano, T. A.,
Peterson, E. P.,
Rasper, D. M.,
Timkey, T.,
Garcia-Calvo, M.,
Houtzager, V. M.,
Nordstrom, P. A.,
Roy, S.,
Vaillancourt, J. P.,
Chapman, K. T.,
and Nicholson, D. W.
(1997)
J. Biol. Chem.
272,
17907-17911[Abstract/Free Full Text]
|
| 38.
|
Halenbeck, R.,
MacDonald, H.,
Roulston, A.,
Chen, T. T.,
Conroy, L.,
and Williams, L. T.
(1998)
Curr. Biol.
8,
537-540[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Liu, X.,
Zou, H.,
Slaughter, C.,
and Wang, X.
(1997)
Cell
89,
175-184[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Green, C. D.,
Long, K. S.,
Shi, H.,
and Wolin, S. L.
(1998)
RNA
4,
750-765[Abstract]
|
| 41.
|
Pruijn, G. J. M.,
Wingens, P. A.,
Peters, S. L. M.,
Thijssen, J. P. H.,
and Van Venrooij, W. J.
(1993)
Biochim. Biophys. Acta
1216,
395-401[Medline]
[Order article via Infotrieve]
|
| 42.
|
Pellizzoni, L.,
Lotti, F.,
Rutjes, S. A.,
and Pierandrei-Amaldi, P.
(1998)
J. Mol. Biol.
281,
593-608[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Van Gelder, C. W.,
Thijssen, J. P.,
Klaassen, E. C.,
Sturchler, C.,
Krol, A.,
Van Venrooij, W. J.,
and Pruijn, G. J. M.
(1994)
Nucleic Acids Res.
22,
2498-2506[Abstract/Free Full Text]
|
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
V. Fok, K. Friend, and J. A. Steitz
Epstein-Barr virus noncoding RNAs are confined to the nucleus, whereas their partner, the human La protein, undergoes nucleocytoplasmic shuttling
J. Cell Biol.,
May 8, 2006;
173(3):
319 - 325.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Papucci, N. Schiavone, E. Witort, M. Donnini, A. Lapucci, A. Tempestini, L. Formigli, S. Zecchi-Orlandini, G. Orlandini, G. Carella, et al.
Coenzyme Q10 Prevents Apoptosis by Inhibiting Mitochondrial Depolarization Independently of Its Free Radical Scavenging Property
J. Biol. Chem.,
July 18, 2003;
278(30):
28220 - 28228.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Spångberg, L. Wiklund, and S. Schwartz
Binding of the La autoantigen to the hepatitis C virus 3' untranslated region protects the RNA from rapid degradation in vitro
J. Gen. Virol.,
January 1, 2001;
82(1):
113 - 120.
[Abstract]
[Full Text]
|
 |
|